Novo Nordisk has added about 2,000 employees this year as it reshapes its workforce after massive layoffs in 2025, according to a Bloomberg report.
Shift from cuts to targeted hiring
The hiring marks a strategic shift for the Danish drugmaker, which ended last year with about 7,800 fewer employees after making its biggest round of layoffs to date under CEO Mike Doustdar. The layoffs were part of a broad restructuring effort aimed at streamlining operations and redirecting resources to faster-growing segments, particularly its successful portfolio of diabetes and obesity drugs.
According to Bloomberg, the latest hiring reflects a more targeted approach to workforce planning, with Novo Nordisk focusing on strengthening capabilities in priority areas rather than across-the-board expansion. The company is said to be hiring in line with its long-term growth strategy, even as it maintains tighter cost controls after last year’s cuts.
The restructuring comes as Novo Nordisk navigates market dynamics, including growing global demand for the weight-loss cure and increasing competition from rivals developing similar therapies. Its obesity drugs, which have seen increased demand in recent years, remain central to its growth ambitions, forcing the company to realign its workforce to better support manufacturing, research and commercialization efforts.
Balancing efficiency with growth
Bloomberg reported that the overhaul of the company’s workforce is part of a broader effort by Doustdar to improve efficiency while ensuring Novo Nordisk remains competitive in a rapidly evolving pharmaceutical environment. By reducing roles in some areas and expanding in others, the company appears to be recalibrating its organizational structure to match changing business priorities.
While the company has not released a detailed breakdown of where the job cuts and new hires are concentrated, the scale of layoffs and subsequent hiring underscores the depth of the transformation underway. Cutting nearly 7,800 positions last year represented a major departure from Novo Nordisk’s traditionally steady growth in headcount, signaling a willingness to take more aggressive steps to protect margins and optimize operations.
At the same time, the addition of 2,000 employees this year indicates that the company is entering a new phase of restructuring that is focused on selective investment rather than across-the-board downsizing. Analysts say such moves are common among big drug companies as they struggle to balance cost discipline with the need to sustain innovation and meet growing demand in key therapeutic areas.
The development highlights the challenges facing global drugmakers as they adapt to changing healthcare needs, pricing pressures and increased competition. For Novo Nordisk, the dual approach of cutting and hiring reflects an effort to remain agile while doubling down on its core strengths in treating chronic diseases.
Industry observers note that the company’s recalibration also reflects a broader trend across the pharmaceutical sector, where firms are increasingly reallocating talent toward high-value therapies and digital capabilities. This shift often involves difficult trade-offs, including workforce reductions in older or lower-growth areas, even as hiring accelerates in more strategic divisions.
Novo Nordisk has not commented publicly, and further clarification of the scope and geographic spread of its hiring and firing is expected in upcoming disclosures.
